Blocking mTOR activity by rapamycin can promote memory cell precursors (Araki et al., 2009), especially the newly differentiated memory CD8+T cells equipped with more superior anti-tumor activity than IL-2-inducing effector T cells (Rao et al., 2010). The gene discussed is CD8A; the disease is neoplasm.